| Objective:To evaluate and compare the efficacy and toxicity in advanced non-small-cell lung cancer (NSCLC) patients treated by paclitaxel plus carboplatin and paclitaxel plus dicycloplatin regimensMethod:140 patients with untreated pathologically confirmed stageâ…¢B orâ…£NSCLC were randomly assigned to one of two groups:the trial group was treated with dicycloplatin 450 mg/m2 on day 1 plus paclitaxel 175 mg/m2 on day 1 every 3 weeks ( PCb);and the group was treated with carboplatin AUC 5 on day 1 plus paclitaxel 175 mg/m2 on day 1 every 3 weeks ( PD) .Treatment efficacy was evaluated every two cycles based on the RESIST standard.All patients received at least two cycles of therapy.Results: Patients received a total of 583 cycles of treatment, all were evaluable for efficacy and toxicity.Median time to progression were 4.9 months and 4.1 months (P<0.05) in PD group and PCb group, and the response rate,the median survival time and 1-year survival rate were 34.2% , 10.5 months , 45.03% and35.7%,10.6 months ,36.02% respectively (P>0.05).The following adverse effects of the two groups were different:the incidence rate of leucopenia was 48.6%(34/70)and 74.3%(52/70) in the trial group and the control group respectively, hand and foot feeling disturbance was 52.9%(37/70) and 18.6%(23/70). show statistical difference in two groups. Other blood-system and non-blood system is similar to the incidence of adverse reactions,no statistical difference.Conclusions: Advanced non-small-cell lung cancer (NSCLC) patients treated by paclitaxel plus carboplatin and paclitaxel plus dicycloplatin regimens is similar to the response rate,the median survival time and 1-year survival rate,However,the trial group is longer than the control group in the median time to progression,and there is statistical difference.In toxicity, hand and foot feeling disturbance of paclitaxel plus dicycloplatin regimens is obvious,a higher incidence of bone marrow suppression in the control group. |
PDF Full Text Request